Aigen Investment Management, LP Ultragenyx Pharmaceutical Inc. Transaction History

Aigen Investment Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$34.92 - $46.66 $80,735 - $107,877	2,312 Added 52.31%	6,732 $239,000
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $165,087 - $230,503	4,420 New	4,420 $203,000
Q2 2022 Aug 02, 2022	SELL	$45.8 - $85.4 $640,375 - $1.19 Million	-13,982 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$62.2 - $84.4 $869,680 - $1.18 Million	13,982 New	13,982 $1.02 Million
Q3 2021 Nov 12, 2021	SELL	$77.92 - $102.4 $582,685 - $765,747	-7,478 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$92.19 - $115.71 $506,952 - $636,289	5,499 Added 277.87%	7,478 $713,000
Q1 2021 May 11, 2021	SELL	$106.9 - $167.73 $998,232 - $1.57 Million	-9,338 Reduced 82.51%	1,979 $225,000
Q4 2020 Feb 12, 2021	SELL	$84.4 - $177.39 $433,225 - $910,542	-5,133 Reduced 31.2%	11,317 $1.57 Million
Q3 2020 Nov 06, 2020	BUY	$72.98 - $90.0 $1.2 Million - $1.48 Million	16,450 New	16,450 $1.35 Million
Q2 2020 Aug 10, 2020	SELL	$46.91 - $78.22 $1.04 Million - $1.74 Million	-22,207 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$33.8 - $62.9 $161,834 - $301,165	-4,788 Reduced 17.74%	22,207 $987,000
Q4 2019 Feb 04, 2020	BUY	$36.08 - $45.83 $973,979 - $1.24 Million	26,995 New	26,995 $1.15 Million

324

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.